Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study.
about
Fibroblast growth factor 23, iron and inflammation - are they related in early stages of chronic kidney disease?Hypophosphatemic rickets: revealing novel control points for phosphate homeostasis.Potentially life-threatening phosphate diabetes induced by ferric carboxymaltose injection: a case report and review of the literature.Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose.Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease.High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic ratsIntravenous iron administration and hypophosphatemia in clinical practice.Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and AnemiaEffects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.Effects of Iron on Vitamin D Metabolism: A Systematic Review.Systemic Control of Bone Homeostasis by FGF23 Signaling.Ferric carboxymaltose: a review of its use in iron deficiency.Novel Faces of Fibroblast Growth Factor 23 (FGF23): Iron Deficiency, Inflammation, Insulin Resistance, Left Ventricular Hypertrophy, Proteinuria and Acute Kidney Injury.Current misconceptions in diagnosis and management of iron deficiencyA controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy.Ferric carboxymaltose reduces the number of red blood cell units transfused and allows transfusion independence to be obtained in patients with iron deficiency anemia secondary to gastrointestinal chronic blood loss.The safety of available treatment options for iron-deficiency anemia.
P2860
Q33904467-26FD5EEA-AFDE-443A-92BB-C017FF0DD819Q34069793-45471D70-8AEC-40CC-9AC2-0B5310CF5242Q34588573-03704B58-8FB8-4316-A0DB-D27D9FB537E8Q34700903-2EF98408-51F0-419E-BF3B-6B032E99FF91Q35067500-683B936B-F58B-4837-8AA8-AFE9B7126923Q35077013-1969829C-C2F1-45FD-B6AC-7710BD157857Q35591336-F607314E-F281-486C-8639-3DFF1BDA1226Q35893998-F0032918-E1AE-46D9-B5C2-250015600D85Q36194460-2B1479D5-AF22-4A84-A367-302D445998AEQ36234188-CF8F3548-C425-4214-A458-1ED183F1DD81Q36843642-2135D654-E906-41D2-85B4-BA04F89413C8Q38271890-2FC4D320-181E-4482-9812-9CE018AD5044Q39003429-3ED69986-BA81-48A7-8CD7-D014CE8E7ACBQ41547046-A3A2E68E-9114-4FA2-8E36-0F0DA54A8152Q47428974-5B36BE3A-9DBE-47A3-9918-877CF48C7062Q48008043-16087F59-EDDA-4EAC-BF36-7D689B6FF87CQ48548255-B81D7BA8-EF39-4464-A8E5-F53CD2CF2BBE
P2860
Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Effect of ferric carboxymaltos ...... alysis of a prospective study.
@ast
Effect of ferric carboxymaltos ...... alysis of a prospective study.
@en
Effect of ferric carboxymaltos ...... alysis of a prospective study.
@nl
type
label
Effect of ferric carboxymaltos ...... alysis of a prospective study.
@ast
Effect of ferric carboxymaltos ...... alysis of a prospective study.
@en
Effect of ferric carboxymaltos ...... alysis of a prospective study.
@nl
prefLabel
Effect of ferric carboxymaltos ...... alysis of a prospective study.
@ast
Effect of ferric carboxymaltos ...... alysis of a prospective study.
@en
Effect of ferric carboxymaltos ...... alysis of a prospective study.
@nl
P2093
P2860
P356
P1433
P1476
Effect of ferric carboxymaltos ...... alysis of a prospective study.
@en
P2093
Alberto Martinez Vea
Carmen Cabré
Carmen García
Manel Jariod
Merche Prats
Ramon Font
P2860
P356
10.1186/1471-2369-14-167
P577
2013-07-31T00:00:00Z